Institution Directory

Clinical trials at Huntsman Cancer Institute (University of Utah)

Sites in Salt Lake City, UT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1140

Shown on this page

Current sort

Live official records

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Bortezomib; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 99,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2041
U.S. locations: 142
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more

Conditions: Epilepsy
Interventions: NEUROPACE RNS SYSTEM, EMU; Device · Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 64 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Houston, Texas • Salt Lake City, Utah

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Moderate Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 61 more

Conditions: Rectal Cancer, Rectal Tumor, Rectal/Anal
Interventions: CG-100 intraluminal bypass device, Stoma; Device · Procedure
Lead sponsor: Colospan Ltd.; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Irvine, California • San Diego, California • Aurora, Colorado + 3 more

Conditions: Brain Metastases
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Interventions: Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy; Procedure · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more

Conditions: Family Caregivers, Dementia, Financial Wellbeing, Financial Coaching
Interventions: Financial Counseling and Advocacy; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 25 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging; Procedure · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 275
States / cities: Birmingham, Alabama • Clovis, California • Concord, California + 195 more

Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 493
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more

Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Drug · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 90
States / cities: Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more

About this Huntsman Cancer Institute (University of Utah) institution page

What this page lists: ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Huntsman Cancer Institute (University of Utah)

Filter and sort this campus

Live official records

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

About this Huntsman Cancer Institute (University of Utah) institution page